Tracking long-term outcomes for CRPS after neridronate treatment
Part of Brain & nervous system clinical trials.
This study is a registry that tracks people with Complex Regional Pain Syndrome (CRPS) who already received neridronate infusions in a previous trial. It looks at how they do over the long term to learn more about the treatment's lasting effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been part of the CRPS-RISE study (the earlier trial for CRPS).
- You must have received all 4 infusions of neridronate (a drug given through an IV) or the matching placebo during that trial.
- You must have completed the final clinic visit at about 6 weeks after the last infusion.
- If you also took part in the open-label extension (a follow-up phase where everyone received the drug), you need to have completed the same 4 infusions and the final visit there too.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives an extended course of neridronate infusions to people who completed the earlier AMBTX-01-301 trial, to see if longer treatment safely keeps easing their chronic pain and other symptoms of complex regional pain syndrome (a long-lasting pain condition, often after an injury).
This trial tests if an intravenous medicine called AMBTX-01 (neridronate) can help people with early-stage Complex Regional Pain Syndrome (CRPS) type 1. It focuses on those whose affected limb feels warm, looks red, and is swollen.
This study tests whether a conservative treatment plan can help people with complex regional pain syndrome (CRPS), a condition where pain lasts longer than expected after an injury. You may qualify if you have had CRPS symptoms for up to 5 years and are between ages 18 and 70.
This trial tests whether low-dose naltrexone can reduce symptoms of complex regional pain syndrome (CRPS), a long-lasting pain condition in an arm or leg. It may help by targeting pain signaling, but you must meet specific CRPS diagnosis and medication rules to join.
This trial tests whether a low dose of naltrexone, a medication that may help calm overactive immune and pain signals, can reduce pain and improve daily life in people with complex regional pain syndrome (CRPS), a chronic condition that often causes severe pain and swelling.
This study tests a comprehensive rehabilitation program for adults with complex regional pain syndrome (CRPS), a chronic pain condition usually affecting one arm or leg. It looks at how the program affects pain and brain function, aiming to improve daily life.
Hear when a new Complex Regional Pain Syndrome I (CRPS I) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.